China Pharma Holding (China Pharma Holding) ROCE % : -52.70% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China Pharma Holding's annualized ROCE % for the quarter that ended in Dec. 2023 was -52.70%.

China Pharma Holding ROCE % Historical Data

The historical data trend for China Pharma Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding ROCE % Chart

China Pharma Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-85.78

-23.49

-26.15

-41.18

-37.36

China Pharma Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-108.39	-30.31	-34.37	-42.29	-52.70

China Pharma Holding ROCE % Calculation

China Pharma Holding's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2.745	/	( ( (17.784 - 12.739)	+	(16.469 - 6.821) )	/ 2 )
	=	-2.745	/	( (5.045	+	9.648)	/ 2 )
	=	-2.745	/	7.3465
	=	-37.36 %

China Pharma Holding's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-4.728	/	( ( (15.352 - 7.058)	+	(16.469 - 6.821) )	/ 2 )
	=	-4.728	/	( ( 8.294	+	9.648 )	/ 2 )
	=	-4.728	/	8.971
	=	-52.70 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

China Pharma Holding (OTCPK:CPHI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China Pharma Holding ROCE % Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

China Pharma Holding (China Pharma Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216

Website

https://www.chinapharmaholdings.com

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

Executives

Ke Deng	10 percent owner	NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung	officer: Chief Financial Officer	72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett	director	4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang	director	NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong	director	NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui	director, 10 percent owner	FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li	officer: President and CEO	2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang	officer: Secretary	NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu	officer: CFO	2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond	10 percent owner	174 FM 1830, ARGYLE TX 76226
David F Brigante	10 percent owner	174FM 1830, ARGYLE TX 76226
Marat Rosenberg	10 percent owner	17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp	10 percent owner	174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc	10 percent owner	174 FM 1830, ARGYLE TX 76226
Timothy P Halter	director, 10 percent owner, officer: CEO, President & CFO	174 FM 1830, ARGYLE TX 76226